The Myers Lab is at the forefront of basic and clinical investigations into human biology and disease. Using cutting-edge genomic technologies and high-throughput next-generation sequencing, we are advancing understanding of gene regulatory systems and how these mechanisms are altered during inception and progression of human disease. One facet of our laboratory is technological development, in which we create innovative techniques to examine molecular entities both individually and genome-wide. We are active members of the ENCylopedia Of DNA Elements (ENCODE) Consortium, producing genome-wide measurements of gene expression, transcription factor binding, and DNA methylation to identify and characterize functional elements within the human genome. We are also comprised of an experienced team of computational biologists that analyze large datasets effectively using the latest developments in analytical tools. Through our application of these genomic resources, we are enhancing our understanding of the biology of human disease and discovering clinically translatable genomic signatures that may impact the diagnosis and treatment of patients.

The Myers Lab is supported in part by the National Institutes of Health (P30CA013148,P50GM115279, R01CA200653, R01MH110472, U01HG007301, U01MH105653, UL1TR001417, and UM1HG009411), the CHDI Foundation, Inc. (A-11369), the Pritzker Neuropsychiatric Disorders Research Fund LLC, and the Daniel Foundation. The content of this website is solely the responsibility of the authors and does not necessarily represent the official views of the sponsors.